David F. Jarrard MDProfessor and Vice Chair, Department of Urology, University of Wisconsin School of Medicine; Associate Director, UW Carbone Cancer Center, Madison, Wisconsin
David Frazier Jarrard, MD, is a tenured Professor of Surgery and Molecular and Environmental Toxicology at the University of Wisconsin. He obtained his BA and MD from the University of Virginia and completed a Urologic Surgery residency at the University Of Chicago Hospitals. He was a fellow in Urologic Oncology at the Brady Urologic Institute of the Johns Hopkins Hospital. He is currently Vice Chair for the Department of Urology, an Associate Director at the UW Carbone Cancer Center, leads the Section of Urologic Oncology, and holds the John Livesey Chair in Urologic Oncology. Dr. Jarrard has served on numerous American Urological Association committees and is President-Elect for the North Central Section. He is Past President for the Society for Basic Urologic Research and serves on the boards of the Society for Urologic Oncology (Member at large) and Society for Academic Urology (Treasurer).
He has active basic science and translational research interests supported through the National Institutes of Health and the Department of Defense Prostate Cancer Research Programs. His clinical work concentrates on advanced Urologic Oncology and improving cancer detection and outcomes. Awards include the Society for Basic Urologic Research (SBUR) Young Investigator and Distinguished Service Awards, Madison Magazine’s ‘Best Physicians in Wisconsin’, Castle Connolly ‘Top Doctors’, ‘Best Doctor in America™’ and the Society for Urologic Oncology Distinguished Service Award. Dr. Jarrard has published numerous chapters, articles and abstracts in the field of prostate cancer.
DisclosuresDr. Jarrard reports no disclosures.
Recent Contributions to PracticeUpdate:
- PSA Response and Treatment Adherence to Apalutamide in Patients With Nonmetastatic CRPC
- TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Outcomes With Abiraterone or Enzalutamide in mCRPC
- Second-Line Chemotherapy vs an Androgen Receptor–Targeted Agent for Metastatic Castration-Resistant Prostate Cancer
- Effect of Abiraterone Acetate and Prednisone on PSA and Radiographic Disease Progression in Patients With Non-Metastatic Castration-Resistant Prostate Cancer
- Impact of Local Treatment on Overall Survival in Patients With Metastatic Prostate Cancer on Diagnosis